Showing 1 - 10 of 21
Currently, health state values are usually obtained from members of the general public trying to imagine what the state would be like rather than by patients who are actually in the various states of health. Valuations of a health state by patients tend to vary from those of the general...
Persistent link: https://www.econbiz.de/10005243061
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of golimumab (Schering-Plough/Centocor) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of active and progressive psoriatic arthritis (PsA) in patients who have...
Persistent link: https://www.econbiz.de/10009653282
Persistent link: https://www.econbiz.de/10010614392
Background: To assess the cost effectiveness of healthcare interventions from a societal perspective, it is necessary to include costs such as patients' travel costs and the opportunity cost of patients' time spent consuming healthcare. Objective: To analyse patients' travel and time costs...
Persistent link: https://www.econbiz.de/10005448993
Background: The Disability in Strategies for Care (DISC) study was the first large randomised controlled trial to compare alternative treatment strategies in the acute treatment of migraine. With 835 patients in its intention-to-treat efficacy analysis, DISC compared a stratified care strategy,...
Persistent link: https://www.econbiz.de/10005449017
The National Institute for Health and Clinical Excellence (NICE) is required to consider cost effectiveness when issuing guidance about the use of health technologies within the UK NHS. Cost effectiveness is a means of supporting a system objective of maximizing population health gain from the...
Persistent link: https://www.econbiz.de/10005449021
Persistent link: https://www.econbiz.de/10005449031
Despite the growing use of decision analytic modelling in cost-effectiveness analysis, there is a relatively small literature on what constitutes good practice in decision analysis. The aim of this paper is to consider the concept of `validity' and `quality' in this area of evaluation, and to...
Persistent link: https://www.econbiz.de/10005449154
Markov models are often employed to represent stochastic processes, that is, random processes that evolve over time. In a healthcare context, Markov models are particularly suited to modelling chronic disease. In this article, we describe the use of Markov models for economic evaluation of...
Persistent link: https://www.econbiz.de/10005449186
The use of decision-analytic modelling for the purpose of health technology assessment (HTA) has increased dramatically in recent years. Several guidelines for best practice have emerged in the literature; however, there is no agreed standard for what constitutes a `good model' or how models...
Persistent link: https://www.econbiz.de/10005449234